Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Amgen (AMGN) Receives a Hold from Bernstein

Tipranks - Tipranks - Wed Apr 22, 7:54AM CDT

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen today and set a price target of $335.00.

Claim 30% Off TipRanks

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company. According to TipRanks, Breen has an average return of 15.3% and an 81.25% success rate on recommended stocks.

In addition to Bernstein, Amgen also received a Hold from Barclays’s Emily Field in a report issued today. However, on April 15, Bank of America Securities reiterated a Sell rating on Amgen (NASDAQ: AMGN).

See today’s best-performing stocks on TipRanks >>

Based on Amgen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.9 billion and a net profit of $1.33 billion. In comparison, last year the company earned a revenue of $9.09 billion and had a net profit of $627 million

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).